Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study-Reference-Cited by-同舟云学术

Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study

Published:2017-06 Issue:6 Volume:18 Page:792-802
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Chandran Smita S,Somerville Robert P T,Yang James C,Sherry Richard M,Klebanoff Christopher A,Goff Stephanie L,Wunderlich John R,Danforth David N,Zlott Daniel,Paria Biman C,Sabesan Arvind C,Srivastava Abhishek K,Xi Liqiang,Pham Trinh H,Raffeld Mark,White Donald E,Toomey Mary Ann,Rosenberg Steven A,Kammula Udai S

Publisher

Elsevier BV

Subject

Oncology

Reference34 articles.

1. Incidence of noncutaneous melanomas in the US;McLaughlin;Cancer,2005

2. The genetics of uveal melanoma: an emerging framework for targeted therapy;Harbour;Pigment Cell Melanoma Res,2012

3. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi;Van Raamsdonk;Nature,2009

4. Mutations in GNA11 in uveal melanoma;Van Raamsdonk;N Engl J Med,2010

5. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15;Arch Ophthalmol,2001

Cited by 220 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Uveal Melanoma: Comprehensive Review of Its Pathophysiology, Diagnosis, Treatment, and Future Perspectives;Biomedicines;2024-08-05

2. The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19;Seminars in Hematology;2024-08

3. Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma;Immuno-Oncology and Technology;2024-08

4. Current status and perspectives of clinical trials for tumor-infiltrating lymphocyte therapy;Clinical and Translational Oncology;2024-07-30

5. Enhancing the activation of T cells through anti‐CD3/CD28 magnetic beads by adjusting the antibody ratio;IUBMB Life;2024-07-24